A.CulottaV
Ozempic as an add-on to basal insulin and Ozempic 1 mg vs 2 mg Primary endpoint: change in A1C from baseline SUSTAIN 5: add-on basal insulin 1,10,11 In adult patients with type 2 diabetes on basal insulin metformin Mean change in A1C from baseline at Week 30 Mean baseline A1C: SUSTAIN FORTE: Ozempic 1 mg vs 2 mg 1,8 In patients with type 2 diabetes on metformin sulfonylurea Mean change in A1C from baseline at Week 40 Mean baseline A1C: Results for SUSTAIN 5 and SUSTAIN FORTE based on sensitivity analyses of retrieved dropout population
Crit Rev Food Sci Nutr 63(33):1192511941 Horvat A, Vlai I, tefulj J, Oroli N, Jazvinak Jembrek M (2023) Flavonols as a potential pharmacological intervention for alleviating cognitive decline in diabetes: evidence from preclinical studies
Which procedures are not covered by BCBSTX
found that treatment with GLP-1RA leads to a 17% reduction in a broad composite kidney endpoint (development of new-onset macroalbuminuria, doubling of serum creatinine or 40% greater decline in estimated glomerular filtration rate (eGFR), progression to end-stage kidney disease, or kidney-related death), mainly as a result of a reduction in new-onset macroalbuminuria (15)
